AstraZeneca’s BACE inhibitor AZD3293 moves forward to a Phase 2/3 trial, joining Merck’s MK-8931 as the most advanced current compounds in this class.
It’s not just for tugging APP around the neuron: The SORLA receptor may also bind Aβ and hasten its demise.
In a cell culture system, astrocytes from people with ALS kill motor neurons. The model could yield more discoveries about the fundamental biology of this disease.
Researchers have identified the striatum as a site of neurogenesis in the adult brain, but not in people with Huntington’s disease.
In Fragile X syndrome, mRNA from the mutant FMR1 gene binds to its own DNA to suppress protein expression. Could the same thing happen in other repeat expansion diseases?